Document Classification

Section Type: RESULTS

Text: Of those who completed 16 weeks of treatment, metformin use, as compared with placebo, was associated with improved glycemic control (mean daily glucose at 16 weeks 7. 8 vs. 8. 8 mmol/l, P = 0. 006 ; mean GHb 6. 9 vs. 7. 6 %, P < 0. 0001) ; reduced insulin requirements (63. 8 vs. 71. 3 IU, P < 0. 0001) ; reduced weight gain (-0. 4 vs. +1. 2 kg, P < 0. 01) ; and decreased plasma LDL cholesterol (-0. 21 vs. -0. 02 mmol/l, P < 0. 01).